When should NSAIDs be used in covid-19?
Article written by Christine Clark The use of NSAIDs in early covid-19 needs more research, according to retired GP and researcher, Dr Colin Brown.
The latest coronavirus developments and scientific research on prevention and treatment.
Article written by Christine Clark The use of NSAIDs in early covid-19 needs more research, according to retired GP and researcher, Dr Colin Brown.
Article written by Christine Clark In the early days of the coronavirus pandemic there was concern that the use of non-steroidal anti-inflammatory drugs might be harmful and people… read more.
Article written by Christine Clark The similarities between the ACE-inhibitor cough and the cough of covid-19 prompted Dr Colin Brown, a retired GP and researcher, to investigate further.
Article written by Christine Clark The similarities between the ACE-inhibitor cough and the cough of covid-19 prompted Dr Colin Brown, a retired GP and researcher, to investigate further.
Article written by Christine Clark Retired GP and researcher Dr Colin Brown realised that the similarities between the ACEI cough and covid-19 cough suggested a common cause and… read more.
Article written by Bruce Sylvester. Current smokers and those with chronic obstructive pulmonary disease COPD suffer greater COVID-19 severity and greater COVID-19 related mortality..
Article written by Christine Clark Two recent systematic reviews have examined the use of masks
Global regulators have held a workshop designed to nail down the data they will require of companies developing vaccines against COVID-19.
The European Medicines Agency will welcome a new Executive Director by the end of 2020. The change comes as the EU drug watchdog’s current chief, Guido Rasi, is… read more.
Verrica Pharmaceuticals Inc. announced that the Company received a letter from the FDA as part of the FDA’s ongoing review of the Company’s New Drug Application (NDA) for… read more.
Gilead Sciences, Inc. announced additional data on remdesivir, an investigational antiviral for the treatment of COVID-19, adding to the available body of knowledge on treatment outcomes with remdesivir…. read more.
Aldeyra Therapeutics, Inc. announced development plans to support a New Drug Application (NDA) for the novel investigational reactive aldehyde species (RASP) inhibitor reproxalap in dry eye disease …. read more.